List of Excipients in Branded Drug NYSTATIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Chartwell RX LLC	NYSTATIN	nystatin	62135-813	BENTONITE
Chartwell RX LLC	NYSTATIN	nystatin	62135-813	D&C YELLOW NO. 10
Chartwell RX LLC	NYSTATIN	nystatin	62135-813	EDETATE CALCIUM DISODIUM
Chartwell RX LLC	NYSTATIN	nystatin	62135-813	HYDROCHLORIC ACID

Generic Drugs Containing NYSTATIN

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	nystatin	0093-0983	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	nystatin	0093-0983	MAGNESIUM STEARATE
Teva Pharmaceuticals USA Inc	nystatin	0093-0983	MALTODEXTRIN
Teva Pharmaceuticals USA Inc	nystatin	0093-0983	POVIDONE K30

What are the Most Frequently-Used Excipients in NYSTATIN?

# Of NDCs	Excipient
46	ALCOHOL
22	ALGELDRATE
15	ALUMINUM HYDROXIDE
17	ANHYDROUS CITRIC ACID

Nystatin Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

Nystatin is a mature, low-cost polyene antifungal with limited systemic absorption and a fragmented dosage-form market. The strongest commercial opportunities are in taste-masked oral suspensions, longer-retention mucosal products, low-irritancy topical products, pediatric delivery systems, and stability-improved formulations. Patent protection for the active ingredient is largely exhausted, so competitive advantage depends on formulation performance, manufacturing reliability, regulatory execution, and channel access.

What is nystatin and how does its formulation profile affect excipient selection?

Nystatin is a polyene macrolide antifungal used against susceptible Candida species. It is highly potent in vitro but has very low aqueous solubility and is poorly absorbed from the gastrointestinal tract. Oral products therefore act locally in the mouth or gastrointestinal tract rather than providing systemic exposure. Topical and vaginal products deliver nystatin directly to infected tissue. [1,2]

Formulation	Common strength	Primary delivery objective	Main excipient challenge
Oral suspension	100,000 units/mL	Local oral or gastrointestinal treatment	Uniform dosing, sedimentation, taste
Oral tablet or pastille	Product-specific	Local gastrointestinal exposure	Drug release and patient acceptability
Cream or ointment	100,000 units/g or equivalent	Cutaneous delivery	Spreadability, irritation, residue
Powder	Product-specific	Treatment of moist skin folds	Flow, adhesion, moisture control
Vaginal tablet or cream	Product-specific	Local vaginal delivery	Retention, disintegration, leakage
Combination topical product	Product-specific	Antifungal plus anti-inflammatory or antibacterial treatment	Compatibility and regulatory classification

Nystatin is generally handled as a dispersed solid rather than a true aqueous solution. Excipient selection must preserve particle distribution, antifungal potency, microbiological quality, and dose uniformity.

Which physicochemical properties drive the nystatin excipient strategy?

The core properties are:

• Low water solubility.
• Sensitivity to formulation environment and processing conditions.
• Large, structurally complex molecule with limited permeability.
• Local rather than systemic activity in most approved products.
• Unit potency commonly expressed in activity units rather than mass alone.
• Poor suitability for conventional aqueous solution dosage forms.

These characteristics favor suspensions, semisolids, powders, vaginal systems, and specialized particulate or lipid-based delivery systems rather than standard oral solutions.

What excipients are used in approved nystatin products?

Approved and marketed products use different excipient platforms by route. Exact inactive ingredients vary by manufacturer, strength, country, and dosage form. FDA labeling and DailyMed records should control any product-specific comparison. [2-5]

Oral suspension excipients

Nystatin oral suspensions commonly use combinations of:

• Purified water as the vehicle.
• Sucrose or another sweetener.
• Cellulosic suspending agents such as carboxymethylcellulose.
• Buffers, often phosphate-based.
• Preservatives such as methylparaben and propylparaben.
• Flavoring agents.
• Wetting or dispersing aids.

The commercial function of each class is direct:

Excipient class	Function	Commercial issue
Sucrose or noncariogenic sweetener	Taste masking and viscosity	Dental burden, diabetes positioning, pediatric use
Cellulose polymer	Suspension stability and viscosity	Pourability and dose withdrawal
Buffer	pH control	Chemical stability and preservative performance
Parabens or alternative preservative	Microbial protection	Label sensitivity and preservative perception
Flavor	Palatability	Pediatric acceptance and regional preferences
Surfactant or wetting aid	Particle wetting	Foaming, irritation, and taste

The largest opportunity is often not a new active ingredient but a better suspension. A product that remains uniform after storage, resuspends with limited shaking, and delivers a reproducible dose can compete against low-cost products in pediatric and caregiver-driven markets.

Topical cream and ointment excipients

Topical products may use petrolatum, mineral oil, propylene glycol, emulsifiers, fatty alcohols, waxes, and water-based cream systems. The choice determines whether the product is occlusive, washable, rapidly absorbed into the stratum corneum, or suitable for intertriginous areas.

An ointment platform can improve residence time and barrier protection but may feel greasy. A cream can improve cosmetic acceptability and patient compliance but may have lower persistence under moisture or friction. A hydrogel or emulgel can create a differentiated product, although nystatin loading and physical stability require development work.

Vaginal formulation excipients

Vaginal tablets and creams use excipients that control:

• Disintegration or dissolution.
• Mucosal retention.
• Leakage after administration.
• Compatibility with vaginal pH.
• Local irritation.
• Microbiological quality.

Mucoadhesive polymers, bioadhesive gels, thermoresponsive systems, and vaginal films are potential development platforms. Their commercial value depends on whether they reduce dosing frequency, leakage, mess, or treatment discontinuation.

What formulation patents protect nystatin products?

Nystatin's active-ingredient composition is mature and generally does not provide a meaningful new chemical entity patent barrier. Commercial protection is more likely to arise from:

1. Specific excipient ratios.
2. Particle-size distributions.
3. Stabilized suspension systems.
4. Taste-masked compositions.
5. Mucoadhesive or controlled-release delivery systems.
6. Combination products.
7. Manufacturing processes that improve potency or uniformity.
8. Device or packaging configurations.
9. Narrow method-of-use claims.

A formulation patent must create a defensible technical distinction. A broad claim covering "nystatin with pharmaceutically acceptable excipients" would face substantial validity and obviousness risk because standard nystatin dosage forms and excipient classes are well established.

What is the Orange Book status of nystatin?

Nystatin is marketed in multiple prescription dosage forms, but it does not have the exclusivity profile of a recently approved branded drug. The FDA Orange Book records approved drug products and any listed patents or exclusivity associated with particular applications. [3]

For nystatin, the practical regulatory position is:

Issue	Assessment
New chemical entity exclusivity	Not relevant to this mature active ingredient
Orphan exclusivity	Not a standard feature of core nystatin products
Pediatric exclusivity	Product-specific and not a general nystatin barrier
Listed formulation patents	Must be reviewed by application and dosage form
Generic substitution	Well established for several dosage forms
Biosimilar pathway	Not applicable
Main competitive barrier	Formulation quality, manufacturing, distribution, and brand position

A company should not assume that a formulation patent covering one nystatin product extends to all dosage forms. Cream, suspension, powder, vaginal, and combination products are separate regulatory and claim-analysis categories.

When does nystatin lose exclusivity, and what generic entry risks exist?

Nystatin's basic active-ingredient exclusivity expired long ago. The relevant question is not when nystatin itself loses exclusivity. It is whether a specific formulation, combination, delivery device, or manufacturing process has enforceable remaining protection.

Generic entry risk is high for conventional nystatin products because:

• The active ingredient is established.
• Clinical use is well characterized.
• Many dosage forms have simple local delivery mechanisms.
• The products are usually inexpensive.
• Prescribers have extensive familiarity with nystatin.
• Substitution and pharmacy-channel competition pressure pricing.

The highest generic exposure is in conventional creams, ointments, powders, and oral suspensions with standard excipient systems. Lower exposure may exist for differentiated products that demonstrate meaningful advantages in adherence, dosing accuracy, residence time, tolerability, or storage stability.

How do Paragraph IV challenges affect nystatin?

Paragraph IV litigation is most relevant when an ANDA applicant challenges listed patents for a reference product. [6] Nystatin is less likely to generate major Paragraph IV activity than a high-revenue specialty drug because:

• Market prices are generally low.
• Multiple generic suppliers may already exist.
• Revenue available to fund litigation is limited.
• Many conventional dosage forms have no substantial remaining patent barrier.

A Paragraph IV opportunity could arise for a newly developed nystatin formulation with meaningful commercial sales. The risk would be highest where the formulation patent relies on predictable excipient substitutions or routine optimization. It would be lower where the patent has strong comparative data showing unexpected stability, improved mucosal retention, or materially better patient outcomes.

How strong is the nystatin patent estate?

The nystatin patent estate is weak at the molecule level and potentially moderate at the formulation level.

Patent layer	Relative strength	Business implication
Nystatin molecule	Low	No meaningful modern composition-of-matter moat
Conventional cream or ointment	Low	Rapid generic pressure
Standard oral suspension	Low to moderate	Differentiation must be measurable
Taste-masked pediatric suspension	Moderate	Potential protection if claims are technically narrow and clinically useful
Mucoadhesive vaginal delivery	Moderate	Opportunity for composition and method claims
Nanoparticle or lipid delivery	Moderate to high initially	Higher development and regulatory burden
Manufacturing process	Moderate	Useful if difficult to design around and linked to quality attributes
Combination therapy	Variable	Depends on active ingredients, indication, and prior art

A stronger portfolio would combine composition claims, process claims, use claims, and device or packaging claims. Claim breadth must reflect actual product performance. Nystatin's extensive prior art makes unsupported functional claims vulnerable.

What excipient strategies offer the best commercial opportunities?

1. Pediatric taste-masked oral suspension

Pediatric oral suspension is the clearest near-term opportunity. The product should target:

• Reduced bitterness.
• Lower required shake time.
• Accurate dosing after storage.
• Low-sugar or sugar-free positioning.
• Preservative flexibility.
• Improved syringe withdrawal.
• Longer in-use stability.

Potential technologies include polymeric taste barriers, ion-exchange resins, cyclodextrin complexes, lipid coating, and optimized flavor systems. The principal risk is that a taste-masking excipient can reduce drug release or interfere with local mucosal exposure.

A successful product could support a formulation patent, a 505(b)(2) strategy in some circumstances, or an ANDA where the formulation remains pharmaceutically equivalent. The regulatory pathway depends on the extent of formulation change and the reference product selected. [7]

2. Low-irritancy topical cream

Topical nystatin products can be differentiated through:

• Reduced greasiness.
• Better spreadability.
• Lower sting on inflamed skin.
• Faster drying.
• Improved performance under occlusion.
• Compatibility with pediatric and sensitive-skin use.
• Packaging that limits contamination.

Excipient choices include nonionic emulsifiers, mild humectants, silicone-based slip agents, polymeric thickeners, and reduced-irritancy solvent systems. The product should avoid unnecessary complexity because each added excipient creates compatibility, labeling, and manufacturing work.

3. Moisture-control powder

Nystatin powders for skin folds can target candidal intertrigo and other moist environments. A commercial formulation could combine antifungal delivery with:

• Improved powder flow.
• Reduced clumping.
• Better skin adhesion.
• Moisture absorption.
• Controlled particle deposition.
• Low-dust packaging.

The key risk is inhalation exposure during application, especially in pediatric or household settings. Packaging and particle engineering are as important as the powder composition.

4. Mucoadhesive vaginal delivery

Vaginal products have an opportunity to reduce leakage and dosing frequency. Candidate excipients include carbomers, polycarbophil, cellulose derivatives, poloxamers, and other bioadhesive polymers.

A commercial product would need evidence for:

• Retention at the treatment site.
• Drug release over the intended interval.
• Minimal irritation.
• Compatibility with condoms or other barrier methods, where relevant.
• Stable potency during storage.
• Acceptable administration experience.

This category has stronger differentiation potential than a conventional cream but also requires more extensive development and user testing.

5. Lipid and particulate delivery systems

Nystatin can be incorporated into lipid-based carriers, nanosuspensions, liposomes, solid lipid particles, or polymeric systems. These technologies may improve wetting, dispersion, tissue residence, or local delivery.

Their commercial limitations are significant:

• Higher manufacturing cost.
• More complex characterization.
• Scale-up risk.
• Potentially difficult equivalence assessment.
• Greater sensitivity to process variation.
• Uncertain reimbursement for a low-cost antifungal.

These systems are most commercially credible where they solve a clear clinical problem, such as difficult-to-treat mucosal disease, recurrent local infection, or poor adherence to conventional products.

What FDA regulatory pathways apply to nystatin reformulation?

The likely pathway depends on whether the proposed product is pharmaceutically equivalent to an approved reference product.

Development approach	Likely pathway	Main evidence burden
Same dosage form and equivalent formulation	ANDA	Pharmaceutical equivalence and bioequivalence or product-specific equivalence
New dosage form or delivery system	505(b)(2) may be appropriate	Bridging, clinical pharmacology, local safety, and efficacy evidence
Novel combination	ANDA or 505(b)(2), depending on reference products	Combination justification and safety
New indication	505(b)(2) or supplemental application	Clinical support for the indication
OTC switch	FDA monograph or application route, depending on product	Monograph compliance, labeling, and switch data

The FDA Inactive Ingredient Database can support excipient selection by identifying prior use levels and routes of administration. It does not establish that a proposed concentration is automatically acceptable in a new formulation. [4]

Which companies are challenging nystatin products?

Nystatin competition is fragmented among generic manufacturers, specialty topical companies, hospital suppliers, and regional pharmaceutical producers. The market does not have a single dominant originator controlling the full product category.

Competitive pressure generally comes from:

• Generic cream and ointment suppliers.
• Manufacturers of oral suspension products.
• Regional vaginal antifungal companies.
• Contract manufacturers supplying private-label products.
• Combination topical product suppliers.

Large generic companies can compete on procurement and pharmacy distribution. Smaller companies can compete through packaging, formulation convenience, pediatric positioning, or specialty distribution.

No biosimilar competition exists because nystatin is a small-molecule antifungal, not a biologic. The relevant competitive threat is generic substitution and private-label manufacturing.

What licensing deals and commercial models are available?

Nystatin licensing opportunities are more likely to involve formulation technology than the active ingredient. Attractive structures include:

• Licensing a taste-masking platform for pediatric suspension.
• Co-development of a mucoadhesive vaginal product.
• Regional commercialization rights for a differentiated topical product.
• Contract manufacturing with technology transfer.
• Private-label supply for hospitals and pharmacy chains.
• Combination-product licensing where the partner owns clinical or distribution assets.

A licensee should avoid paying a premium for "nystatin rights" without control of a differentiated formulation, regulatory dossier, manufacturing process, or channel position. The active ingredient itself offers limited exclusivity value.

What manufacturing and intellectual-property barriers matter most?

The most important barriers are operational rather than molecule-based:

• Consistent nystatin potency measured in activity units.
• Control of particle size and dispersion.
• Suspension uniformity throughout shelf life.
• Microbial control in aqueous products.
• Preservation without unacceptable taste or irritation.
• Scale-up of semisolid texture and rheology.
• Filling accuracy for low-viscosity suspensions.
• Packaging compatibility.
• Protection from light, heat, and moisture where relevant.
• Reproducible process controls for complex carriers.

A formulation patent is more valuable when it protects a process that competitors cannot easily reproduce. Manufacturing know-how, analytical methods, supplier qualification, and stability data can provide practical protection even when formal patent scope is narrow.

What revenue exposure and launch scenarios apply to nystatin?

Nystatin is generally a low-price, high-volume opportunity rather than a premium specialty-drug opportunity. Revenue potential depends on the product's differentiation.

Product concept	Price potential	Generic risk	Commercial outlook
Conventional cream	Low	High	Volume and supply reliability
Standard oral suspension	Low to moderate	High	Pediatric and institutional demand
Sugar-free taste-masked suspension	Moderate	Moderate	Stronger pharmacy and caregiver positioning
Long-retention vaginal product	Moderate	Moderate	Potential adherence advantage
Advanced lipid or nanoparticle product	High per unit	Lower initially	Narrow indication and higher development cost
Private-label topical product	Low	High	Distribution-led opportunity

A conventional generic launch may achieve volume but face rapid price erosion. A differentiated product can delay direct substitution if it has a clear label claim, superior usability, or a protected formulation. The expected return should be modeled against the relatively low baseline price of nystatin products.

How does nystatin compare with competing antifungals?

Nystatin competes with azole antifungals such as clotrimazole, miconazole, ketoconazole, and fluconazole, depending on the indication and route.

Attribute	Nystatin	Topical azoles	Fluconazole
Main use	Local Candida treatment	Local fungal treatment	Systemic and mucosal treatment
Systemic exposure	Very low by oral local-delivery route	Usually low topically	Material systemic exposure
Resistance considerations	Limited systemic use advantage	Variable by organism and setting	Resistance and drug-interaction concerns
Formulation opportunity	High for suspension and mucosal systems	High for creams and gels	Lower excipient differentiation for oral solid forms
Generic pricing pressure	High	High	High
Biosimilar risk	None	None	None

Nystatin's low systemic absorption can support a local-treatment positioning, but it also limits opportunities for systemic indications. Its best commercial strategy is route-specific formulation improvement.

Key Takeaways

• Nystatin's active-ingredient patent protection is effectively exhausted; formulation and manufacturing rights are the relevant IP assets.
• Oral suspension is the strongest near-term excipient opportunity, especially for taste masking, dose uniformity, and sugar-free pediatric use.
• Vaginal mucoadhesive systems offer greater differentiation but require more development and local-safety evidence.
• Topical creams, ointments, and powders face high generic pressure unless they improve irritation, residence time, cosmetic feel, or moisture control.
• Biosimilar competition is not applicable.
• Paragraph IV exposure is generally limited for conventional nystatin products but could become relevant for a commercially successful reformulation.
• The most defensible commercial assets combine formulation claims with process know-how, stability data, packaging, and distribution access.
• Nystatin is better suited to volume, adherence, and specialty-channel strategies than to premium pricing based solely on the active ingredient.

FAQs

Can nystatin be formulated as a true aqueous solution?

Usually not as a conventional high-load aqueous solution. Its low water solubility favors suspensions, dispersions, emulsions, or carrier-based systems.

Is a sugar-free nystatin suspension commercially attractive?

Yes. A sugar-free product can target pediatric patients, patients with diabetes, and caregivers seeking lower dental exposure. The formulation must preserve taste, suspension stability, dose uniformity, and preservative performance.

Can a nystatin formulation qualify for a new patent?

Yes, but the patent must claim a technically distinct composition, process, delivery system, or use. Routine substitution of one standard suspending agent for another is likely to face prior-art and obviousness challenges.

Are nystatin nanoparticles likely to replace conventional creams?

Not broadly. Nanoparticle systems may have value for selected mucosal or difficult-to-treat indications, but conventional creams remain cheaper and simpler to manufacture.

What is the best nystatin product for a specialty pharmaceutical company?

A differentiated pediatric suspension or a longer-retention vaginal product is generally more attractive than another standard cream. Both create clearer opportunities for formulation claims and adherence-based marketing.

References

1. National Center for Biotechnology Information. (2024). Nystatin compound summary. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Nystatin

2. U.S. National Library of Medicine. (2024). DailyMed: Nystatin drug labels. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Food and Drug Administration. (2024). Nystatin product labeling and approved drug information. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

6. U.S. Food and Drug Administration. (2024). ANDA submissions: Amendments and Paragraph IV certifications. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-forms-and-submission-requirements

7. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA. https://www.fda.gov/drugs/development-resources/applications-covered-section-505b2